Smash the mutants
Location: United States
Employees: 11-50
Total raised: $92M
Investors 1
| Date | Name | Website |
| 10.07.2026 | Future Ven... | future.ven... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 30.03.2026 | - | $37M | Structure ... |
| 10.07.2025 | Series A | $45M | Bold Capit... |
| 16.11.2022 | Seed | $10M | - |
Mentions in press and media 16
| Date | Title | Description |
| 31.03.2026 | Universal Vaccine Powerhouse: Centivax Raises $37 Million to Redefine Immunity | Centivax secured $37M, pushing its universal flu vaccine, Centi-Flu 01, towards Phase 2 trials. This capital also accelerates four more universal immunity programs: cancer therapy, malaria vaccine, antivenom, and Alzheimer's prevention. A s... |
| 30.03.2026 | Centivax: $37 Million Raised To Advance Universal Flu Vaccine Into Phase 2 And Expand Immunity Platform | Centivax announced it has raised $37 million in an oversubscribed financing round to accelerate the Phase 2 clinical development of its universal influenza vaccine candidate and advance additional programs toward clinical readiness. The fin... |
| 30.03.2026 | Meiji Seika Pharma: Investment In Vaccine Developer To Advance Universal Immunity Platform | Meiji Seika Pharma has announced a strategic investment in Centivax to accelerate the development of next-generation vaccines designed to provide broad, long-lasting protection against infectious diseases. Centivax is developing a universal... |
| 30.03.2026 | Centivax Raises $37M in Funding | Centivax, a South San Francisco, CA-based developer of a universal flu vaccine, raised $37m in funding. The round was led by Structure Fund (Oliver Mulherin & Sam Altman), with participation from Meiji Seika Pharma Co., Sigmas Group, Ke... |
| 30.03.2026 | Centivax Closes $37 Million Financing | SAN FRANCISCO, CA, Centivax, Inc., a clinical-stage biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, announced the closing of a $37 million oversubscribed financing ... |
| 11.07.2025 | Centivax Secures $45M to Revolutionize Global Immunity | Centivax closed an oversubscribed $45 million Series A funding round. Future Ventures led the investment. This capital fuels the advancement of Centivax’s lead universal flu vaccine candidate. The vaccine will enter Phase I clinical trials ... |
| 10.07.2025 | Centivax Nabs $45M Series A | SOUTH SAN FRANCISCO, CA, Centivax, a biotechnology company engineering vaccines and therapies, announced a $45 million Series A. >> Click here for more funding data on Centivax >> To export Centivax funding data to PDF and Exce... |
| 10.07.2025 | Centivax: $45 Million Series A Raised For Advancing Universal Flu Vaccine | Centivax, a biotech firm developing vaccines and therapies for long-lasting, universal protection against diverse targets, announced it has closed an oversubscribed $45 million Series A funding round. Steve Jurvetson of Future Ventures led ... |
| 09.07.2025 | Centivax Raises $45M in Series A Funding | Centivax, a San Francisco, CA-based immunity company providing a proprietary computational immune-engineering platform, raised $45M in Series A funding. The round was led by Steve Jurvetson of Future Ventures, an early backer of Tesla, Spac... |
| 08.07.2025 | Centivax Raises $45M to Commercialize First Universal Flu Vaccine | What You Should Know: – Centivax, a biotech company developing durable, universal vaccines, today announced the close of a $45 million Series A led by Steve Jurvetson’s Future Ventures, with participation from NFX, BOLD Capital, Base4, Kend... |
Show more